Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01858324
Other study ID # 13-025
Secondary ID
Status Completed
Phase N/A
First received May 14, 2013
Last updated December 2, 2014
Start date March 2014
Est. completion date September 2014

Study information

Verified date December 2014
Source Université de Sherbrooke
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review CommitteeCanada: Ministère santé et services sociaux du Québec
Study type Interventional

Clinical Trial Summary

Hypertensive disorders of pregnancy happen in 5% of pregnancies. Being aware of symptoms and complications may help women to present early and preserve their own and their baby's health.

The proposed research aims to evaluate the impact of educational tools in pregnant women from an ambulatory population. These tools include a detailed pamphlet (including a graphic-based summary), a magnet summarizing symptoms and appropriate action, and a video. Level of knowledge will be evaluated after one month with a validated questionnaire. We will also evaluate if getting more information about preeclampsia increases patient anxiety as well as satisfaction about the tools.


Description:

Background: Preeclampsia is a leading cause of maternal/fetal morbidity/mortality. Pregnant women are often poorly informed on preeclampsia and seeking care too late results in maternal/fetal complications. Many healthcare providers believe that delivering information for low-risk women only make them more anxious.

Preliminary data: We published that an information pamphlet on preeclampsia increases knowledge, without increasing anxiety, and generates high satisfaction in women hospitalized for preeclampsia.

Objectives: Demonstrate that (1) ambulatory low-risk pregnant women will benefit from the pamphlet/video with improved knowledge; (2) without any increase in anxiety, and with great satisfaction.

Design: Prospective randomized controlled pilot study. Inclusion criteria: consecutive pregnant women aged ≥18 y.o. between 200-326 weeks presenting at the clinic and who read/write French or English. Exclusion criteria: Anticipated delivery or termination within one month. Intervention: pamphlet, magnet and video. Control: no educational tool. At baseline, women in both groups will answer questionnaire #1 on demographics; one month later: self-administered questionnaire #2 on knowledge, anxiety, satisfaction.

Sample size: N=178 will provide 80% power to find a significant improvement of at least 20% in knowledge score and 96% power to find a difference of at least 1 on scale for anxiety (alpha of 5%). Assuming a drop-out rate of 10%, missing answers <20%, and rate of answered questionnaire #2 of 50%, 400 subjects will be recruited.

Anticipated results: The tools will improve knowledge by about 20% in intervention group compared to control group. They will not increase anxiety over one point and will be highly appreciated by women.


Recruitment information / eligibility

Status Completed
Enrollment 247
Est. completion date September 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Women between 20+0 to 32+6 weeks pregnant

- Aged 18 years old or more

- Who present at the Blood Sampling in Pregnancy clinic

- With an adequate understanding of written and spoken French or English in order to read the pamphlet and fill out the self-administered questionnaire

Exclusion Criteria:

- Consideration of an interruption of pregnancy for maternal or fetal reasons

- Anticipated delivery within the next month.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Educational tools
Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.

Locations

Country Name City State
Canada Centre Hopitalier Universiatire de Sherbrooke Sherbrooke Quebec

Sponsors (1)

Lead Sponsor Collaborator
Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Sub-group analysis: age Diferences in outcomes between control and intervention groups according to group age 1 month No
Other Sub-group analysis: parity Differences between control and intervention group according to parity. 1 month No
Other Sub-group analysis: pre-pregnancy BMI Differences between control and intervention group according to pre-pregnancy BMI 1 month No
Other Sub-group analysis: category of health care provider Differences between control and intervention group according to category of healthcare provider 1 month No
Other Sub-group analysis: preeclampsia risk factors Differences between control and intervention group according to preeclampsia risk factors (pre-pregnancy diseases or a history of preeclampsia 1 month No
Other Sub-group analysis: tobacco use Differences between control and intervention group according to tobacco use 1 month No
Other Sub-group analysis: Differences between control and intervention group according to employment type 1 month No
Other Sub-group analysis: ethnicity Differences between control and intervention group according to ethnicity 1 month No
Other Sub-group analysis: socio-economic level Differences between control and intervention group according to socio-economic level 1 month No
Other Sub-group analysis: educational level Differences between control and intervention group according to educational level 1 month No
Other Sub-group analysis: marital status Differences between control and intervention group according to marital status 1 month No
Other Sub-group analysis:video viewed on site vs. at home Differences between control and intervention group according to video viewed on-site vs. at home 1 month No
Other Sub-group analysis:delay since last consultation of the tools Differences between control and intervention group according to delay since last consultation of the tools. 1 month No
Primary Knowledge about preeclampsia Through a questionnaire (7 questions, 35 statements, one global score) 1 month No
Secondary Anxiety Question 1: 8 statements (Likert's scale 1 to 6) Question 2 more general 1 month Yes
Secondary Satisfaction 3 questions 1 month No
See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Recruiting NCT03313024 - Berlin-Brandenburg Pregnancy Cohort
Active, not recruiting NCT04990141 - Molecular Screening Method for Preeclampsia (PREMOM)
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT05999851 - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy N/A
Recruiting NCT02923206 - Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis N/A
Terminated NCT02558023 - The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Phase 3
Completed NCT02384226 - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Completed NCT02854501 - Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
Withdrawn NCT05016440 - Lisinopril for Renal Protection in Postpartum Preeclamptic Women N/A
Completed NCT02554604 - Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
Not yet recruiting NCT02541110 - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler N/A
Recruiting NCT02337049 - Preeclampsia Subtypes and Surrogate Markers of CVD Risk N/A
Recruiting NCT02247297 - Pancreatic Stone Protein (PSP) in Pregnant Women
Completed NCT02238704 - Cornell University-Micronutrient Initiative Calcium Supplementation Study N/A
Withdrawn NCT01179542 - The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR N/A
Completed NCT01195441 - Prediction and Prevention of Preeclampsia by First Trimester Ultrasound N/A
Completed NCT00456118 - Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Recruiting NCT00117546 - Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A